Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ERBB2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ERBB2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ERBB2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ERBB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERBB2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERBB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERBB2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERBB2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERBB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00457279 | Breast | Precancer | positive regulation of translation | 32/1080 | 136/18723 | 5.89e-12 | 9.27e-10 | 32 |
GO:00342509 | Breast | Precancer | positive regulation of cellular amide metabolic process | 33/1080 | 162/18723 | 1.72e-10 | 1.77e-08 | 33 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
GO:00506736 | Breast | Precancer | epithelial cell proliferation | 46/1080 | 437/18723 | 6.02e-05 | 1.23e-03 | 46 |
GO:00508637 | Breast | Precancer | regulation of T cell activation | 37/1080 | 329/18723 | 8.04e-05 | 1.56e-03 | 37 |
GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
GO:00071597 | Breast | Precancer | leukocyte cell-cell adhesion | 40/1080 | 371/18723 | 1.07e-04 | 1.94e-03 | 40 |
GO:19021055 | Breast | Precancer | regulation of leukocyte differentiation | 32/1080 | 279/18723 | 1.66e-04 | 2.74e-03 | 32 |
GO:00506786 | Breast | Precancer | regulation of epithelial cell proliferation | 40/1080 | 381/18723 | 1.88e-04 | 3.03e-03 | 40 |
GO:00224079 | Breast | Precancer | regulation of cell-cell adhesion | 45/1080 | 448/18723 | 2.12e-04 | 3.30e-03 | 45 |
GO:19031313 | Breast | Precancer | mononuclear cell differentiation | 43/1080 | 426/18723 | 2.61e-04 | 3.84e-03 | 43 |
GO:19030377 | Breast | Precancer | regulation of leukocyte cell-cell adhesion | 36/1080 | 336/18723 | 2.61e-04 | 3.84e-03 | 36 |
GO:00420633 | Breast | Precancer | gliogenesis | 33/1080 | 301/18723 | 3.06e-04 | 4.40e-03 | 33 |
GO:00160497 | Breast | Precancer | cell growth | 46/1080 | 482/18723 | 5.63e-04 | 7.16e-03 | 46 |
GO:19038299 | Breast | Precancer | positive regulation of cellular protein localization | 30/1080 | 276/18723 | 6.48e-04 | 7.99e-03 | 30 |
GO:00066059 | Breast | Precancer | protein targeting | 33/1080 | 314/18723 | 6.50e-04 | 7.99e-03 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBB2 | SNV | Missense_Mutation | rs121913471 | c.2329N>T | p.Val777Leu | p.V777L | P04626 | protein_coding | deleterious(0.05) | benign(0.036) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
ERBB2 | SNV | Missense_Mutation | | c.2033N>A | p.Arg678Gln | p.R678Q | P04626 | protein_coding | tolerated(0.19) | benign(0.103) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ERBB2 | SNV | Missense_Mutation | | c.2263N>A | p.Leu755Met | p.L755M | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ERBB2 | SNV | Missense_Mutation | | c.2264N>G | p.Leu755Trp | p.L755W | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ERBB2 | SNV | Missense_Mutation | | c.929C>T | p.Ser310Phe | p.S310F | P04626 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ERBB2 | SNV | Missense_Mutation | | c.926N>C | p.Gly309Ala | p.G309A | P04626 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBB2 | SNV | Missense_Mutation | | c.2524N>A | p.Val842Ile | p.V842I | P04626 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264N>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264T>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0AB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264T>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | inhibitor | CHEMBL180022 | NERATINIB | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | Erlotinib | ERLOTINIB | 27900369 |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | PF-05212384 | GEDATOLISIB | 17314276,21325073 |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | TAE-684 | TAE-684 | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | HER-2 Protein AutoVac | | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | AP32788 | | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | GEFITINIB | GEFITINIB | 20151670 |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | Docetaxel | DOCETAXEL | 23801166,27052654,25185099 |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | VS-5584 | VS-5584 | 23270925 |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | | IRESSA | IRESSA | 16470840 |